The adverse metabolic effects of androgen deprivation therapy (ADT) in men with metastatic prostate cancer are clear. This study by Wang et al discusses the relationship between ADT and bone mineral density (BMD) in Japanese men with prostate cancer, a group previously reported to have a lower incidence of baseline and ADT-induced osteoporosis compared with Caucasians.1 Yuasa et al2 provided an interesting article that may lead to additional studies to understand the impact of prostate cancer and its treatment on bone metabolism. This article should also serve as a cautionary note about the appropriate use of ADT for prostate cancer and the use of biomarkers in clinical trials.
展开▼
